SCHEMBL257135

SCHEMBL257135

COc1ccc(Cl)cc1C(=O)Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
KCNMA1 Q12791 4/20 0.56
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 2/20 0.54
POLB P06746 2/20 0.53
TSHR P16473 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
DNMT3A Q9Y6K1 1/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KLF5 Q13887 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3630423 0.93 MRGPRX4 (0.58) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL11306685 0.86 LMNA (0.63) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL1423874 0.85 FLT1 (0.55) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL48961 0.85 MRGPRX4 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL364764 0.85 ALDH1A1 (0.65) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL6542484 0.85 LMNA (0.61) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL30100412 0.85 MRGPRX4 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL7210817 0.83 MRGPRX4 (0.62) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL1095516 0.83 MEN1 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL726267 0.83 MAPT (0.60) LMNAKCNMA1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108586447-B Benzodiazepine compound and preparation method and application thereof 中国人民解放军第四军医大学 2021-01-29 CN disclosed
WO-2019204449-A1 K-RAS MODULATORS WITH A VINYL SULFONE MOIETY THERAS, INC. (US) 2019-10-24 WO disclosed
WO-2019204449-A1 K-RAS MODULATORS WITH A VINYL SULFONE MOIETY THERAS, INC. (US) 2019-10-24 WO disclosed
WO-2019193062-A1 SUBSTITUTED PYRROLIDINES AND THEIR USE ABBVIE S.Á.R.L (LU) 2019-10-10 WO disclosed
US-20170319516-A1 NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2017-11-09 US disclosed
US-20170319516-A1 NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2017-11-09 US disclosed
EP-3026046-A1 THIAZOLES AS CANNABINOID RECEPTOR LIGANDS AbbVie Inc. (US) 2016-06-01 EP disclosed
WO-2016081599-A1 NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-05-26 WO disclosed
US-9340501-B2 Marinopyrrole derivatives as anticancer agents H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2016-05-17 US disclosed
EP-2376462-B1 THIAZOLES AS CANNABINOID RECEPTOR LIGANDS ABBVIE INC (US) 2015-12-16 EP disclosed
US-4158060-A PSYCHOLOGICAL DISORDERS SYNTHELABO (FR) 1979-06-12 US disclosed
US-4158063-A Acylamino(alkyl)benzene derivatives and process for preparing them HOECHST AKTIENGESELLSCHAFT (DE) 1979-06-12 US disclosed
US-4113871-A HYPOGLYCEMICALLY AND HYPOLIPIDEMICALLY ACTIVE DERIVATIVES OF PHENYL-ALKANE-CARBOXYLIC ACIDS BOEHRINGER MANNHEIM GMBH (DE) 1978-09-12 US disclosed
US-4021567-A FOR PSYCHOSOMATIC AND PSYCHOTIC DISTURBANCES SYNTHELABO (FR) 1977-05-03 US disclosed
US-4010279-A BIPHENYLOXY DERIVATIVES AND ANTIHYPERLIPIDEMIC USE BOEHRINGER INGELHEIM GMBH (DT) 1977-03-01 US disclosed
US-3984416-A Substituted quinoline-8-carboxamido ethyl benzene-sulfonyl N-cyclopentylmethyl urea HOECHST AKTIENGESELLSCHAFT (DT) 1976-10-05 US disclosed
US-3965173-A MULTISTAGE, METHYLATION OF 5-CHLOROSALICYLIC ACID CHUBB FRANCIS L 1976-06-22 US disclosed
US-3953449-A ANALGESICS SYNTHELABO (FR) 1976-04-27 US disclosed
US-3932503-A Benzenesulfonyl ureas HOECHST AKTIENGESELLSCHAFT (DT) 1976-01-13 US disclosed
US-3932658-A Composition and method for lower blood sugar containing N-[4-(β-<2-methoxy-5-chloro-benzamido>-ethyl)-benzenesulfonyl]-N'-cyclopentyl-urea HOECHST AKTIENGESELLSCHAFT (DT) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170319516-A1 NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER HADHA, HADHB, TFAM LMNA 3973/4885KCNMA1 3793/4885ALDH1A1 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.